X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Schering-Plough, already hit with a swarm of consumer fraud suits along with Merck, co-producer of the anti-cholesterol drug Vytorin, faces a class action suit by shareholders. The New Orleans firm Kahn Gauthier Swick has filed suit against Schering on behalf of shareholders who purchased shares of stock July 24, 2006 and January 14, 2008, the day the two pharmaceutical companies announced the result of a study that found Vytorin is no more effective at reducing plaque buildup in the arteries than generic drugs costing far less. Manson v Schering-Plough, et al., 2:08-cv-00397. [See related article, " Drug study triggers flood of suits."] The complaint alleges Schering misled investors about the efficacy of Vytorin, a combination of Zetia and Zocor, compared to simvastatin, the generic form of Zocor. Schering stock traded as high as $32 during 2007 but has dropped to less than $20 per share since the Vytorin study results were announced.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

 
 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.